This study is for children with **HIV** (a virus that attacks the body's immune system) who are aged 4 weeks to less than 12 years and weigh less than 45 kg. The study uses a medicine called **Doravirine (DOR)**, which is part of a treatment to help control HIV. The goal is to see how well DOR works and if it is safe for children. Participants must be either new to HIV treatment or have very low virus levels due to ongoing treatment. Children will take DOR with two other medicines, or in a combined pill, for up to 96 weeks, and possibly longer if they join an extension study. The extension could last until the medicine is available in stores or for up to 224 more weeks.

• This study lasts up to 96 weeks, with a possible extension.
• Participants must have **HIV** and meet specific health criteria.
• There are risks involved, like any other medical study, so careful consideration is needed.